Category: CAR T-Cell therapy

Home / Established Year

Mechanism of CAR T Cell therapy

Complete mechanism of CAR T Cell therapy explained

Introduction CAR T cell therapy is a nascent cancer treatment that targets and eliminates cancerous cells by using the body's immune system. Gene modification is done for the expression of chimeric antigen receptors on T cells, w..

Gamma delta T cells Latest option in cancer treatment

Gamma delta T cells: Latest option in cancer treatment

Two types of T-cells There exist two distinct categories of T cells: αβ T cells and γδ T cells. The previous statement describes a T-cell receptor (TCR) that consists of a heterodimer composed of α and β chains. The latter ..

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

CAR T-Cell treatment Chimeric Antigen Receptor (CAR) T-cell treatments, which target antigens that are unique to cancer, have shown amazing results in curing leukemia and lymphoma that has not responded to other treatments or has..

Disruption of CD5 on CAR T Cells Enhances the Effectiveness of Anti-Tumor Treatment

Disruption of CD5 on CAR T Cells Enhances the Effectiveness of Anti-Tumor Treatment

CAR T-Cell therapy in the treatment of cancer A preclinical study conducted by researchers at the University of Pennsylvania's Perelman School of Medicine and Abramson Cancer Center suggests that the use of CRISPR-Cas9 technology..

CAR T-Cell therapy for Chronic Lymphocytic Leukemia

CAR T-Cell therapy for Chronic Lymphocytic Leukemia

Introduction Chronic lymphocytic leukemia (CLL) is a long-lasting condition where mature B lymphocytes, which have encountered antigens before, become cancerous. This leads to the buildup of malignant B cells in the blood, bone m..

Lisocabtagene maraleucel is approved by FDA for relapsed or refractory mantle cell lymphoma

Lisocabtagene maraleucel is approved by FDA for relapsed or refractory mantle cell lymphoma

May 2024: The Food and Drug Administration has granted approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have un..

Risk of developing secondary tumors following CAR-T cell therapy is minimal - A Stanford Study

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

June 2024: The chances of getting secondary blood cancers after CAR-T cell therapy, a cell-based cancer treatment that got a lot of attention in 2017 for being effective against hard-to-treat blood cancers, are very low, according..

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

June 2024: Seattle Children's Hospital will initiate the inaugural clinical trial in the United States this summer to evaluate the efficacy of an autologous CAR T-cell treatment against a prevalent kind of lupus in pediatric patie..

Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation
, , ,

Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation

What is the Richter transformation? Richter transformation is an infrequent but not rare occurrence when an aggressive B-cell lymphoma develops in people with chronic lymphocytic leukemia or small lymphocytic lymphoma. The progno..

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Pancreatic cancer Pancreatic cancer, also referred to as the "king of cancers," is a highly deadly malignant tumor, with a survival rate of fewer than 10% over a 5-year period. As a result of inadequate screening methods, the maj..

Newer Older
Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy